Glioma

Gene Therapy/Cisplatin Combined To Reduce Tumor Growth In Vivo

Published in Cancer Weekly, July 17th, 2001

by Deborah W. Heinrich, PhD, staff medical writer - A new combination of antitelomerase gene therapy and the anticancer drug cisplatin for the treatment of malignant glioma was designed and implemented by researchers at the Mt. Sinai Medical Center in New York.

Y. Kondo and colleagues in the Department of Neurosurgery previously reported successful treatment of malignant glioma with 2',5'-oligoadenylate (2-5A) linked to an antisense oligonucleotide against human telomerase RNA (2-5A-anti-hTR), which binds the RNA portion of the telomerase complex, targeting it for RNaseL cleavage. Telomerase activity, which is responsible for maintaining "chromosome integrity in cancer...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-07-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry